Results 111 to 120 of about 30,028 (235)

Familial heterozygous hypercholesterolemia: a clinical case

, 2016
Резюме. У статті наведено клінічний випадок сімейної гетерозиготної гіперхолестеринемії з розвитком у пацієнтки гострого інфаркту міокарда з подальшим проведенням аортокоронарного шунтування.
М'якінькова, Людмила Олександрівна, Катеренчук, Іван Петрович, Вакуленко, Костянтин Євгенійович, Katerenchuk, I. P., Shabliy, L. M., Vakulenko, K. Ye., Шаблій, Людмила Миколаївна, Miakinkova, L. O.   +7 more
core  

Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method

Practical Laboratory Medicine, 2015
Objectives: It is well known that familial hypercholesterolemia (FH) is a common inherited disorder that can markedly elevate the level of plasma LDL cholesterol.
Hayato Tada, Masa-aki Kawashiri, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi   +6 more
doaj   +1 more source

Familial hypercholesterolemia: current treatment and advances in management

, 2008
Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated.
Huijgen, Roeland, Defesche, Joep C., Vissers, Maud N., Lansberg, Peter J., Kastelein, John J. P., Hutten, Barbara A.   +5 more
core   +1 more source

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

International Journal of the Cardiovascular Academy
Hypercholesterolemia, a major contributor to atherosclerotic cardiovascular disease, remains inadequately controlled despite widespread statin use, particularly in patients with familial hypercholesterolemia or statin intolerance.
Agung Cendekia Putra Nusantara, Ariella Diandihati Rapsanjani, Ikhwan Handirosiyanto, Tara Mandiricha, Aisyah Silvia Gaffar   +4 more
doaj   +1 more source

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale

Lipids in Health and Disease, 2017
Background Statins are generally well-tolerated and serious side effects are infrequent, but some patients experience adverse events and reduce their statin dose or discontinue treatment altogether. Alirocumab is a highly specific, fully human monoclonal
Tamio Teramoto, Akira Kondo, Arihiro Kiyosue, Mariko Harada-Shiba, Yasushi Ishigaki, Kimimasa Tobita, Yumiko Kawabata, Asuka Ozaki, Marie T. Baccara-Dinet, Masataka Sata   +9 more
doaj   +1 more source

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia

Scientific Reports, 2017
Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown.
E. Climent, S. Pérez-Calahorra, V. Marco-Benedí, N. Plana, Rosa Sánchez, E. Ros, J. Ascaso, J. Puzo, F. Almagro, C. Lahoz, F. Civeira, J. Pedro-botet   +11 more
semanticscholar   +1 more source

Relation of peripheral flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia

, 2002
The relation of peripheral flow-mediated vasodilation and coronary arterial calcium was studied in young patients with heterozygous familial hypercholesterolemia (FH) using high-resolution ultrasound and multi-detector computed tomography (MDCT).
Neunteufl, T, Hoffmann, U, Heher, S, Kostner, K, Widhalm, K, Dirisamer, A   +5 more
core   +1 more source

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

, 2017
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Pirillo A, Norata GD, Catapano AL
core  

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.

Journal of Clinical Lipidology, 2018
BACKGROUND Evolocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is safe and effective in reducing low-density lipoprotein cholesterol in adults with familial hypercholesterolemia.
D. Gaudet, G. Langslet, S. Gidding, I. Luirink, A. Ruzza, C. Kurtz, Chen Lu, R. Somaratne, F. Raal, A. Wiegman   +9 more
semanticscholar   +1 more source

Statins for children with familial hypercholesterolemia

, 2014
Background Familial hypercholesterolemia is one of the most common inherited metabolic diseases; the average worldwide prevalence of heterozygous familial hypercholesterolemia is at least 1 in 500.
Kovanen, Petri T., Serena Tonstad, Jaana Kuoppala, Drogari, Euridiki, Vuorio, Alpo, Euridiki Drogari, Albert Wiegman, Alpo Vuorio, Kuoppala, Jaana, Tonstad, Serena, Steve E Humphries, Petri T Kovanen, Humphries, Steve E., Wiegman, Albert   +13 more
core   +2 more sources